Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300241 · ClinicalTrials.gov registry record · Phase 1
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
A Phase 1 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Neomorph.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT07300241: Recruiting Phase 1 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Neomorph.
NCT07300241 is a Phase 1 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Neomorph. The registered enrollment target is 30 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07300241, a Phase 1 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Neomorph.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
Primary Outcome
TEAEs will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0.
Conditions Studied
Interventions
- DRUG NEO-811
Study Locations (7)
New York
- NEO-811 Long Island Site - Lake Success
- NEO-811-101 NYC Site - New York
Texas
- NEO-811 Dallas Site - Dallas
- NEO-811 Houston Site - Houston
Michigan
- NEO-811 Grand Rapids Site - Grand Rapids
South Carolina
- NEO-811 South Carolina Site - Myrtle Beach
Virginia
- NEO-811 Virginia Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT07300241 shows while recruiting
NCT07300241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (88% lower).
The record links to 9 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which NEO-811 is the first listed.
NCT07300241 lists 7 locations in 5 states (New York, Texas, Michigan).
Frequently Asked Questions
What is clinical trial NCT07300241 about?
NCT07300241 is a clinical study titled "Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma". The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
What is the current status of trial NCT07300241?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-19. Estimated completion is 2027-09.
What conditions does trial NCT07300241 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, RCC, Kidney Cancers, Kidney Cancer Metastatic.
What interventions are being tested in trial NCT07300241?
The interventions under investigation include: NEO-811 (DRUG).
Who is sponsoring clinical trial NCT07300241?
This trial is sponsored by Neomorph, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300241 being conducted?
This trial has 7 study locations across Michigan, New York, South Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07300241's enrollment target sits among peer trials
30 93rd of 121 higher than 26 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI